Royal Philips

The Executive Committee, chaired by CEO Roy Jakobs, sets the strategic direction, with R&D allocation and M&A executed at the operational level. Charlotte Hanneman has served as CFO since 2024, overseeing the balance-sheet capacity for acquisitions and internal venture funding. The Board of Management retains final authority on large transactions.

Philips does not operate as a traditional fund-of-funds investor. Its capital deployment is concentrated on internal R&D programs and direct acquisitions of companies in diagnostics, connected care, and health informatics. It runs a blockchain research lab and the Philips Foundation Impact Investments vehicle, but the parent company's primary investing motion is corporate M&A rather than LP commitments.

Lingotto Investment Management LLP, part of the Agnelli family's Exor network, held a 19.2% stake in Royal Philips as of May 2024. This makes Lingotto a major shareholder but not the controlling entity. Philips remains a publicly listed company with its own supervisory and management boards, and there is no operational integration with Exor's other portfolio companies.

Philips concentrates its R&D and acquisition spend on diagnostic imaging, image-guided therapy, patient monitoring, ultrasound, and personal health. Within those domains, it emphasizes software, AI, and data interoperability. The firm does not invest in pure-play pharma, biotech, or health insurance, maintaining a tight focus on medical devices and health informatics.

Yes, the Philips Foundation operates alongside the commercial business with a separate governance structure, chaired by Marnix van Ginneken as Chief ESG & Legal Officer. The foundation deploys impact investments through Philips Foundation Impact Investments B.V., targeting access to care in underserved communities. Those activities are ring-fenced from the parent company's R&D pipeline.